Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mirati Therapeutics
San Diego, California, United Statesmirati.com ↗
- Ownership
- Public · MRTX
- Employees
- ~600
- Development stage
- Other
01
Overview
Mirati Therapeutics developed KRAZATI® (adagrasib), a KRASG12C inhibitor approved for NSCLC. Other programs include MRTX1133 targeting KRASG12D in early clinical trials, and additional assets such as sitravatinib and MRTX1719. Sitravatinib failed its phase 3 trial in NSCLC and is no longer being developed by Mirati for that indication. The pipeline includes both marketed and investigational drugs focused on genetically defined cancers.[6][9]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules[2][1]Targeted therapies[1][2]
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Mirati Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirati Therapeutics.